Highlights:
-TRILOGY-ACS shows no advantage for prasugrel over clopidogrel
-Renal denervation may be cost-effective for resistant hypertension
-German registry shows TAVI restricted to high-risk patients and with in-hospital mortality comparable to surgery
-Profile: David Holmes